Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

1.69
-0.1000-5.59%
Post-market: 1.700.0110+0.65%19:50 EST
Volume:306.04K
Turnover:521.99K
Market Cap:163.41M
PE:-0.73
High:1.79
Open:1.79
Low:1.67
Close:1.79
Loading ...

ADC Therapeutics Sa : Guggenheim Cuts Target Price to $10 From $11

THOMSON REUTERS
·
08 Nov 2024

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
07 Nov 2024

ADC Therapeutics Q3 2024 Adj. EPS $(0.28) Beats $(0.40) Estimate, Sales $18.464M Beat $18.462M Estimate

Benzinga
·
07 Nov 2024

ADC Therapeutics Sa: as of September 30, 2024, Cash and Cash Equivalents Were $274.3 Mln

THOMSON REUTERS
·
07 Nov 2024

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

THOMSON REUTERS
·
07 Nov 2024

ADC Therapeutics Q3 Net Income USD -43.969 Million

THOMSON REUTERS
·
07 Nov 2024

Press Release: ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Dow Jones
·
07 Nov 2024

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

Zacks
·
06 Nov 2024

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

PR Newswire
·
05 Nov 2024

ADC Therapeutics to Present at November Investor Conferences

PR Newswire
·
04 Nov 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
02 Nov 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Zacks
·
01 Nov 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

PR Newswire
·
31 Oct 2024

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)

Simply Wall St.
·
28 Oct 2024

ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains

Simply Wall St.
·
11 Oct 2024

ADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA’s Phase 2 Study

TIPRANKS
·
02 Oct 2024